Shibadas Biswal on Muck Rack

Shibadas Biswal

As seen in: Nature, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Shibadas

Contact Shibadas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children - npj Vaccines

|
By Heather Friberg, Xavier Sáez-Llorens, Shibadas Biswal, Ian Escudero, Manja Brose
| Nature Verified
Abstract As robust cellular responses are important for protection against dengue, this phase 2 study evaluated the kinetics and phenotype of T cell responses induced by TAK-003, a live-attenuated tetravalent dengue vaccine, in 4–16-year-old living in dengue-endemic countries (NCT02948829). Two hundred participants received TAK-003 on Days 1 and 90.
Open in Who Shared Issue with article?

Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial

|
By Takeda Vaccines, Luis Vargas, Shibadas Biswal, Charissa Borja-Tabora
| The Lancet Verified
Summary Background A substantial unmet need remains for safe and effective vaccines against dengue virus disease, particularly for individuals who are dengue-naive and those younger than 9 years. We aimed to assess the efficacy, safety, and immunogenicity of a live attenuated tetravalent dengue vaccine (TAK-003) in healthy children aged 4–16 years.
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified